why choose us

First received: May 31, 2023

Clinical Trial: Kisspeptin Administration Subcutaneously to Patients With IHH

Study Status: Completed

Recruit Status: RECRUITING

Condition: Hypogonadotropic Hypogonadism

Study Type: INTERVENTIONAL


Official Title: Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Brief Summary: We are recruiting men and women with Idiopathic Hypogonadotropic Hypogonadism (IHH).Kisspeptin will be administered subcutaneously (SC) for 2-weeks in a pulsatile fashion.Ultrasound monitoring of ovarian follicular growth (for women) and frequent blood sampling (q10 minutes for up to 70 minutes) will be performed to assess the physiologic response to kisspeptin over time.

Read more